Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3092
Abstract: The PIKTAM study evaluated the efficacy and safety of the PI3K inhibitor buparlisib in combination with tamoxifen in hormone receptor‐positive (HR+), HER2‐negative advanced breast cancer patients after failure of prior endocrine therapy. In this open‐label,… read more here.
Keywords: hormone receptor; positive her2; receptor positive; buparlisib combination ... See more keywords
A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34161
Abstract: The heterogeneity of hormone receptor (HR)‐positive, HER2‐negative early breast cancers reinforces the importance of individualized, risk‐adapted treatment approaches. Numerous factors contribute to the risk for recurrence, including clinical tumor features, individual biomarkers, and genomic risk.… read more here.
Keywords: her2 negative; treatment approaches; negative early; risk ... See more keywords
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
Sign Up to like & getrecommendations! Published in 2019 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-019-05134-x
Abstract: PurposePalbociclib is approved in 1st line for hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC). A Compassionate Access Programme previously allowed patients to receive it in 4th line. However, Palbociclib has not been specifically tested… read more here.
Keywords: positive her2; her2 negative; breast cancer;
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
Sign Up to like & getrecommendations! Published in 2022 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-022-06535-1
Abstract: Despite advances in adjuvant therapeutic strategies, many patients with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) experience disease recurrence, even many years after primary surgery. The aim of this review is: (i) to point out… read more here.
Keywords: risk; treatment; risk stratification; positive her2 ... See more keywords
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
Sign Up to like & getrecommendations! Published in 2017 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-017-1784-1
Abstract: BackgroundEverolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced breast cancer. It is necessary, therefore, to characterize the safety profile of this new combination in the real-world clinical setting… read more here.
Keywords: trial; positive her2; safety; breast cancer ... See more keywords
The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical breast cancer"
DOI: 10.1016/j.clbc.2021.10.007
Abstract: Endocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the… read more here.
Keywords: patients positive; chemotherapy; negative mbc; her2 negative ... See more keywords
Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systemic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2023.2203485
Abstract: ABSTRACT Background The rate of pathological complete response (pCR) with both chemotherapy alone (CT) and endocrine therapy (ET) in the neoadjuvant (Na) treatment of hormone receptor (HR)-positive/HER2-negative breast cancer (BC) is unsatisfactory. Limited data on… read more here.
Keywords: her2 negative; analysis; endocrine therapy; positive her2 ... See more keywords
The Genomic Landscape of Mucinous Breast Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djy216
Abstract: Mucinous carcinoma of the breast (MCB) is a rare histologic form of estrogen receptor (ER)-positive/HER2-negative breast cancer (BC) characterized by tumor cells floating in lakes of mucin. We assessed the genomic landscape of 32 MCBs… read more here.
Keywords: breast; positive her2; breast cancer; cancer ... See more keywords
Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djz023
Abstract: While invasive ductal breast cancer (IDC) represents the most common histological type of breast cancer, minor subtypes exist such as mucinous breast cancer (MuBC). MuBC patients are generally older and have an excellent prognosis while… read more here.
Keywords: positive her2; breast cancer; data mubc; cancer ... See more keywords
Abstract PD8-01: Race and age differences in PAM50 biomarker status in the Carolina breast cancer study
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs16-pd8-01
Abstract: Background: African American breast cancer patients have lower relative frequency of hormone receptor (HR)-positive/HER2-negative disease and higher subtype-specific mortality. However, few population-based studies have RNA-based subtyping data, and racial differences in the biology of HR-positive/HER2-negative… read more here.
Keywords: breast; race; age; positive her2 ... See more keywords
Abstract P2-09-32: Ki-67 index value and progesterone receptor status predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor positive and HER2 negative tumors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs17-p2-09-32
Abstract: Background: Breast cancer is no longer a single disease with high molecular heterogeneity. Gene profiling has identified at least 4 subtypes: Luminal A, Luminal B, HER2-enriched and basal-like breast cancer. Moreover, immunohistochemistry (IHC) classification is… read more here.
Keywords: positive her2; value; breast cancer; cancer ... See more keywords